NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital leads $67.5 million (€64.4 million) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
Proceeds of financing will support two double-blinded Phase 2 trials for its lead candidate XC001, a pioneering transformative gene therapy approach for the treatment of severe cardiovascular disease. This investment builds on Jeito's expertise in cardiology,...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Rafaèle Tordjman, Founder and CEO of Jeito, is awarded Chevalier of the Légion d’Honneur
Paris, France, 30 September 2020 – Jeito Capital (“Jeito”), a rapidly emerging independent...
Jeito Capital co-leads $110 Million Series A Financing in Neogene Therapeutics
Neogene becomes Jeito Capital’s first investment following the fund I launch in January 2020 Round...
Rafaèle Tordjman launches JEITO CAPITAL, a new private equity company dedicated to biotech-biopharmaceuticals
Paris, January 13, 2020 - Rafaèle Tordjman launches JEITO CAPITAL, a new French and independent...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.